ホーム › びまん性大細胞型B細胞リンパ腫 › ニューヨーク › New York City
New York City、NYにおけるびまん性大細胞型B細胞リンパ腫の臨床試験
New York Cityとその周辺地域（約30マイル以内）の拠点で、びまん性大細胞型B細胞リンパ腫に関する21件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
被験者募集中第1/2相
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
被験者募集中第2相
- Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
被験者募集中第3相
- Icahn School of Medicine at Mount Sinai ( Site 0164), New York
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
被験者募集中第2相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108), New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
被験者募集中第1相
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
被験者募集中第1相
- Columbia University, New York
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center, New York
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
被験者募集中第1相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
A Study of ARC-02 in B-cell NHL
被験者募集中第1相
- NYU Langone, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
被験者募集中第1/2相
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
DALY II USA/ MB-CART2019.1 for DLBCL
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center, New York
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center, New York
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
被験者募集中早期第1相
- Memorial Sloan Kettering Cancer Center, New York
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
被験者募集中第2相
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
被験者募集中
- Columbia University, New York
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
被験者募集中第2相
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
被験者募集中
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only), New York
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center, New York
他の都市におけるびまん性大細胞型B細胞リンパ腫の試験
- Baldwin Park, CA19件の研究
- Chicago, IL18件の研究
- Houston, TX17件の研究
- Los Angeles, CA17件の研究
- Milwaukee, WI16件の研究
- Boston, MA16件の研究
- Nashville, TN15件の研究
- Philadelphia, PA15件の研究
- Portland, OR15件の研究
- Durham, NC14件の研究
- Dallas, TX13件の研究
- Washington, DC12件の研究
New York Cityにおける他の研究
- 乳がん136件の研究
- 非小細胞肺癌121件の研究
- がん（全種類）109件の研究
- 前立腺がん103件の研究
- 転移性癌93件の研究
- 大腸癌78件の研究
- 卵巣がん69件の研究
- 肺がん60件の研究
- 多発性骨髄腫60件の研究
- 膵臓がん60件の研究
- 子宮内膜がん52件の研究
- 急性骨髄性白血病51件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。